Research Topics
Genomes and Genes | C Kent OsborneSummaryAffiliation: Baylor College of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancerC Kent Osborne
Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
Breast 12:362-7. 2003..In turn, ER located in the cell membrane can activate the growth factor receptor pathways. Breast tumors with high levels of AIB1 and HER-2 may be resistant to tamoxifen because of an increase in its estrogen agonist activity...
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne
Lester and Sue Smith Breast Center and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 17:1147-59. 2011..This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor (ER)-positive metastatic breast cancer...
Mechanisms of endocrine resistance in breast cancerC Kent Osborne
Dan L Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Annu Rev Med 62:233-47. 2011..Results of recent clinical studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies...- Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyGrazia Arpino
Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
J Natl Cancer Inst 99:694-705. 2007..We investigated whether blockade of all HER homo- and heterodimer pairs by combined treatment with several inhibitors could more effectively inhibit tumor growth in such models... - Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistanceGrazia Arpino
Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
J Natl Cancer Inst 97:1254-61. 2005..As in laboratory models, lack of PR expression in ER+ tumors may be a surrogate marker of aberrant growth factor signaling that could contribute to the tamoxifen resistance observed in these tumors... - Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou
The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 96:926-35. 2004..Gefitinib's ability to eliminate this cross-talk and to restore tamoxifen's antitumor effects should be tested in the clinic... - Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton
The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
Cancer Res 68:7493-501. 2008..Over time, the molecular phenotype of breast cancer can change... - Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancersYee-Lu Tham
Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
Breast Cancer Res Treat 94:279-84. 2005..Docetaxel acts therapeutically by inducing apoptosis and this can be used as a marker of response... - Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesAlbert C Chen
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
Breast Cancer Res Treat 134:583-93. 2012..These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive... - Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patientsJenny C Chang
Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
Breast Cancer Res Treat 108:233-40. 2008..008). We have established molecular profiles of sensitivity to docetaxel. RT-PCR technology provides a potential platform for a predictive test of docetaxel chemosensitivity using small amounts of routinely processed material... - Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez
Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 23:2469-76. 2005..CONCLUSION: The molecular pathways driving tumor growth can change as the tumor progresses. Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance... - Neoadjuvant trastuzumab induces apoptosis in primary breast cancersSyed K Mohsin
Breast Center at Baylor College of Medicine/The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
J Clin Oncol 23:2460-8. 2005..02). CONCLUSION: In primary breast cancers, trastuzumab substantially induces apoptosis, providing a molecular explanation for both its therapeutic efficacy and its successful combination with cytotoxic chemotherapy... - Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patientsJenny C Chang
Breast Center, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
J Clin Oncol 23:1169-77. 2005..Chemotherapy for operable breast cancer decreases the risk of death. Docetaxel is one of the most active agents in breast cancer, but resistance or incomplete response is frequent... - Low SAFB levels are associated with worse outcome in breast cancer patientsStephanie Hammerich-Hille
Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
Breast Cancer Res Treat 121:503-9. 2010..This study shows that low SAFB protein levels predict poor prognosis of breast cancer patients, suggesting critical functions of SAFB1 and SAFB2 in breast cancer cells... - Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerIlenia Migliaccio
Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Room N1110, Houston, TX 77030, USA
Breast Cancer Res Treat 123:651-60. 2010..0001) when compared with patients with PR-/IRS-1- tumors. In conclusion, nuclear IRS-1 may be a useful marker to predict tamoxifen response in patients with early breast cancer, particularly when assessed in combination with PR... - Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in miceTracy E Strecker
Breast Center, Department of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 101:107-13. 2009..Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients. These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer... - Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton
Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Breast Cancer Res 12:R40. 2010..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype... - Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapyXiaojiang Cui
Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Clin Oncol 23:7721-35. 2005..Finally, we will consider the clinical implications of these observations... - β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinibCatherine Huang
Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77054, USA
Breast Cancer Res 13:R84. 2011..The β1 integrin resides on the membrane of the breast cancer cell, activating several elements of breast tumor progression including proliferation and survival... - Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi
Lester and Sue Smith Breast Center, Margaret M and Albert B Alkek Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 17:1351-61. 2011.... - HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group studyGrazia Arpino
Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
Clin Cancer Res 10:5670-6. 2004.... - Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesMichelle D Martin
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
Breast Cancer Res Treat 95:7-12. 2006..Tamoxifen and/or anthracylcene-based chemotherapies eliminated all MTA1 associations with clinical outcome, suggesting MTA1 overexpression predicts early disease relapse, but sensitizes breast tumors to systemic therapies... - Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsRachel Schiff
Department of Medicine, Baylor College of Medicine, Breast Center room N1230, One Baylor Plaza MS 600, Houston, TX 77030, USA
Cancer Chemother Pharmacol 56:10-20. 2005.... - Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin
Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
Breast Cancer Res Treat 94:205-11. 2005..Proliferation, determined by Ki67 staining, was not significantly changed. Clinical trials of this type are difficult to carry out and modifications in trial design are needed to make this process more efficient... - Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressorShiming Jiang
The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Mol Endocrinol 20:311-20. 2006..The coexpression of these proteins in breast cancer specimens, and the combined recruitment (and release) of SAFB1/2 and N-CoR furthermore suggests that this interaction has functional relevance... - Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistanceRachel Schiff
Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Clin Cancer Res 10:331S-6S. 2004..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective... - Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptorAshby J Morrison
Department of Molecular and Cellular Biology and The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Mol Endocrinol 17:1543-54. 2003.... - Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 95:353-61. 2003.... - Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trialSusan G Hilsenbeck
Breast Center and Department of Medicine, Baylor College of Medicine, One Baylor Plaza BCM 600, Houston, TX 77030, USA
Clin Cancer Res 12:1049s-1055s. 2006..We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy... - Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Cancer 116:1234-42. 2010..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy... - Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancerC Kent Osborne
Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
Clin Cancer Res 11:865s-70s. 2005..This process can be delayed or reversed by simultaneous treatment with growth factor pathway inhibitors. This strategy is now being tested in clinical trials... - Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistanceGrazia Arpino
Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Endocr Rev 29:217-33. 2008.... - Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersBhuvanesh Dave
Lester and Sue Smith Breast Center, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 29:166-73. 2011..Understanding of the cellular response to HER2-targeted therapies is needed to tailor treatments and to identify patients less likely to benefit... - Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancerTorsten A Hopp
Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Clin Cancer Res 10:7490-9. 2004..The clinical value of the second recently identified ER isoform, called ER-beta, is less clear, and there is currently conflicting data concerning its potential role as a prognostic or predictive factor... - Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumorsChunhua Lu
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 95:1825-33. 2003..We examined whether ZD1839 blocks signal transduction and prevents the development of ER-negative breast cancer... - The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthJana Divisova
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
Breast Cancer Res Treat 98:315-27. 2006..This data supports previous studies indicating a role for GH/IGF in mammary gland development, and suggests that pegvisomant maybe useful for the prevention and/or treatment of estrogen receptor positive breast cancer... - Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivationYen Chao Wang
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
Breast Cancer Res 13:R121. 2011..Here we investigate resistance mechanisms to each drug alone, or to their combination using a large panel of HER2-positive cell lines made resistant to these drugs... - Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapyC Kent Osborne
The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
Breast 14:458-65. 2005.... - Estrogen-receptor biology: continuing progress and therapeutic implicationsC Kent Osborne
Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600 Houston, TX 77030, USA
J Clin Oncol 23:1616-22. 2005 - Biological mechanisms and clinical implications of endocrine resistance in breast cancerMario Giuliano
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
Breast 20:S42-9. 2011.... - A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesisJessica D Kessler
Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Science 335:348-53. 2012..Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers... - Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerRachel Schiff
Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
Breast Cancer Res 7:205-11. 2005..Preclinical data suggest that blockade of selected growth factor receptor signaling can overcome this type of resistance, and this strategy is already being tested in clinical trials... - Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databasesValerie-Jeanne Bardou
Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
J Clin Oncol 21:1973-9. 2003..Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients... - Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 63:2434-9. 2003..These results suggest that ERbeta expression is not a surrogate for ERalpha in clinical breast tumors and, as such, could be a useful biomarker in its own right... - Multicenter phase II study of oral bexarotene for patients with metastatic breast cancerFrancisco J Esteva
University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
J Clin Oncol 21:999-1006. 2003..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent... - Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerJenny C Chang
Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA
Lancet 362:362-9. 2003..Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel... - Aromatase inhibitors: future directionsC Kent Osborne
Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
J Steroid Biochem Mol Biol 95:183-7. 2005.... - Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate responseRachel Schiff
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 9:447S-54S. 2003..Thus, the interactions of these diverse elements are essential considerations in defining new predictive and therapeutic tools... - Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancerLois C Friedman
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
J Behav Med 30:351-7. 2007..89, p = .004, respectively). Patients may benefit from a discussion with their oncologists and other healthcare providers about self-forgiveness and the potential benefits of reducing self-blame to facilitate adjustment to breast cancer... - Role of molecular and genetic markers in breast cancer treatment decisionsC Kent Osborne
Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
J Clin Oncol 21:285s-287s. 2003 - Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphataseTingting Sun
Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Cell 144:703-18. 2011.... - Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growthYongmin Liu
Department of Medicine, Breast Center, Baylor College of Medicine, Houston Texas, TX 77030, USA
Oncogene 21:7680-9. 2002..These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer... - Insights into the role of progesterone receptors in breast cancerSuzanne A W Fuqua
J Clin Oncol 23:931-2; author reply 932-3. 2005 - Enhanced gene expression in breast cancer cells in vitro and tumors in vivoHuanzhang Lu
Center for Cell and Gene Therapy, National Cancer Institute, National Institutes of Health, Building 10, Room 2A27, Bethesda, Maryland 20892, USA
Mol Ther 6:783-92. 2002..Furthermore, expression profiling can facilitate the design of optimal expression plasmids for use in specific cancers... - Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialAnthony Howell
Christie Hospital and Holt Radium Institute, Manchester, UK
J Clin Oncol 22:1605-13. 2004.... - Intrinsic resistance of tumorigenic breast cancer cells to chemotherapyXiaoxian Li
Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
J Natl Cancer Inst 100:672-9. 2008.... - Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionSuleiman Massarweh
Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
Cancer Res 68:826-33. 2008..This study provides a rationale to combine HER inhibitors with tamoxifen in clinical studies, even in tumors that do not initially overexpress EGFR/HER2... - Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
J Clin Oncol 23:5973-82. 2005..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established... - The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao Jun Ma
AviaraDx Inc, Carlsbad, CA, USA
J Clin Oncol 24:4611-9. 2006..Confirmation in larger independent patient cohorts was needed to fully validate their clinical utility... - Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistanceSusan Cleator
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
Breast Cancer Res Treat 95:229-33. 2006..Larger validation studies are necessary to define and refine patterns for different agents... - Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancerSuleiman Massarweh
Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
Cancer Res 66:8266-73. 2006..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal... - Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman
Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109-0368, USA
Breast Cancer Res Treat 90:1-3. 2005 - Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
N Engl J Med 349:17-26. 2003..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse... - Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010Laura F Hutchins
University of Arkansas for Medical Sciences, Little Rock, AR, USA
J Clin Oncol 23:8313-21. 2005..05). CONCLUSION: CAF did not improve DFS compared with CMF; there was a slight effect on OS. Given greater toxicity, we cannot conclude CAF to be superior to CMF. TAM is effective in HR-positive disease, but not in HR-negative disease... - Spreading the word, but not too thinlyAnthony Howell
Lancet 363:165-6. 2004 - Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsAnthony Howell
Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
Cancer 104:236-9. 2005..The authors reported the overall survival results from these studies... - Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 11:861s-4s. 2005 - Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancerLori J Pierce
Southwest Oncology Group, San Antonio, TX, USA
J Clin Oncol 23:24-9. 2005..04; P = .54). CONCLUSION: The current analysis does not suggest an adverse effect on local or systemic control with CONC versus SEQ TAM and RT in node-negative breast cancer. A randomized trial is encouraged to validate these results... - Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results ofSaul E Rivkin
Swedish Cancer Institute, Seattle, Washington, USA
Cancer 97:21-9. 2003..CONCLUSIONS: The authors conclude that, after 20 years of follow-up, adjuvant chemotherapy with CMFVP remains superior to L-PAM for the treatment of patients with lymph node positive breast carcinoma... - Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancerLi Hua Wang
Basic Research Program, SAIC Frederick, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
Cancer Cell 10:487-99. 2006..DIBA does not affect phosphorylation of HER2, MAPK, AKT, and AIB1, suggesting that DIBA-modified ERalpha may induce a switch from agonistic to antagonistic effects of TAM on resistant breast cancer cells... - Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statementSteven E Come
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Clin Cancer Res 9:443S-6S. 2003 - Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden
Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
J Clin Oncol 25:656-61. 2007.... - Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)Kishan J Pandya
University of Rochester, James P Wilmot Cancer Center, Rochester, New York 14642, USA
Am J Clin Oncol 30:113-25. 2007.... - Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsJohn F R Robertson
Department of Surgery, Nottingham City Hospital, Nottingham, United Kingdom
Cancer 98:229-38. 2003....
Research Grants
- TRANSLATIONAL RESEARCH IN BREAST CANCERC Osborne; Fiscal Year: 2007..8) Our highly successful Developmental Projects Program and Career Development Program will continue to encourage new ideas and new investigators in translational breast cancer research. ..
- Baylor College of Medicine Cancer CenterC Osborne; Fiscal Year: 2005..To Develop Increased Support for Programs in the Shared Resources/Cores; and 4. To Recruit Additional Faculty to Strengthen Existing Programs and Support Additional Program Development. ..
- TRANSLATIONAL RESEARCH IN BREAST CANCERC Osborne; Fiscal Year: 2007..8) Our highly successful Developmental Projects Program and Career Development Program will continue to encourage new ideas and new investigators in translational breast cancer research. ..
- Baylor College of Medicine Cancer CenterC Osborne; Fiscal Year: 2007....